IGM Biosciences Operating Income

IGM Biosciences (IGMS) currently reports a operating income of $-62M as of June 2025. That compares with $-240M in the prior-year period — up 73.9% year over year. Use the charts on this page to explore IGM Biosciences's operating income history and peer comparisons.

IGM Biosciences's operating income increased from $-240M to $-62M — a 73.9% year-over-year increase (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

IGM Biosciences reported $-62M in operating income as of June 2025. That compares with $-240M in the prior-year period — up 73.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-62M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for IGM Biosciences, and consider following IGMS for alerts when major investors trade the stock.

IGM Biosciences is classified in the Healthcare sector. On operating income, it currently shows $-62M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IGMS with unrelated industries.